Low-molecular-weight heparins do not modify obliterative airway disease in rat tracheal allografts

REFERENCES

• Boehler A, Estenne M: Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007–1018.
   PubMed Web of Science ®Google Scholar
• Fujita M, Ishihara M, Ono K, Matsumura K, Saito Y, Yura H, Morimoto Y, Shimizu M, Takase B, Ozaki S, Kikuchi M, Maehara T: Inhibition of neointimal proliferation in balloon-injured arteries using non-anticoagulant heparin-carrying polystyrene. J Cardiovasc Pharmacol. 2004;43:31–38.
   PubMed Web of Science ®Google Scholar
• Kazi M, Lundmark K, Religa P, Gouda I, Larm O, Ray A, Swedenborg J, Hedin U: Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins. J Cell Physiol. 2002;193:365–372.
   PubMed Web of Science ®Google Scholar
• Kanabar V, Hirst SJ, O'Connor BJ, Page CP: Some structural determinants of the antiproliferative effect of heparinlike molecules on human airway smooth muscle. Br J Pharmacol. 2005;146:370–377.
   PubMed Web of Science ®Google Scholar
• Garg HG, Hales CA, Yu L, Butler M, Islam T, Xie J, Linhardt RJ: Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative. Carbohydr Res. 2006;341:2607– 2612.
   PubMed Web of Science ®Google Scholar
• Al-Ansari E, Du HK, Yu L, Ochoa CD, Garg HG, Quinn DA, Hales CA: Low-molecular-weight heparin inhibits hypoxic pulmonary hypertension and vascular remodeling in guinea pigs. Chest. 2007;132:1898–1905.
   PubMed Web of Science ®Google Scholar
• Baram D, Rashkovsky M, Hershkoviz R, Drucker I, Reshef T, Ben-Shitrit S, Mekori YA: Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation. Clin Exp Immunol. 1997;110: 485–491.
   PubMed Web of Science ®Google Scholar
• Hochart H, Jenkins PV, Smith OP, White B: Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol. 2006;133:62–67.
   PubMed Web of Science ®Google Scholar
• Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR, Naparstek Y: Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol. 1990;20:493– 499.
   PubMed Web of Science ®Google Scholar
• Shapira OM, Rene H, Lider O, Pfeffermann RA, Shemin RJ, Cohen IR: Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin. J Surg Res. 1999;85:83– 87.
   PubMed Web of Science ®Google Scholar
• Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, Cohen IR: Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest. 1989;83:752–756.
   PubMed Web of Science ®Google Scholar
• Teranishi K, Poston RS, Reitz BA, Robbins RC: Effect of low molecular weight heparin on graft vascular disease in the rat cardiac allograft model. Transplant Proc. 1999;31:103–105.
   PubMed Web of Science ®Google Scholar
• Hisatomi K: Effect of low-molecular-weight heparin on development of cardiac allograft vascular disease following heart transplantation in rats. Transplant Proc. 1998;30:4337–4339.
   PubMed Web of Science ®Google Scholar
• Gottmann U, Mueller-Falcke A, Schnuelle P, Birck R, Nickeleit V, Van Der Woude FJ, Yard BA, Braun C: Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys. Transpl Int. 2007;20:542–549.
   PubMed Web of Science ®Google Scholar
• Braun C, Schultz M, Fang L, Schaub M, Back WE, Herr D, Laux V, Rohmeiss P, Schnuelle P, Van Der Woude FJ: Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin). Transplantation. 2001;72:209–215.
   PubMed Web of Science ®Google Scholar
• Byrne GW, Schirmer JM, Fass DN, Teotia SS, Kremers WK, Xu H, Naziruddin B, Tazelaar HD, Logan JS, McGregor CG: Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant. 2005;5:1011–1020.
   PubMed Web of Science ®Google Scholar
• Antus B, Fillinger J, Sebe A, Jeney C, Soltesz I, Horvath I: No gender difference in development of obliterative airway disease in rat tracheal allografts. Exp Mol Pathol. 2006;81: 235–238.
   PubMed Web of Science ®Google Scholar
• Szende B, Paku S, Rácz G, Kopper L: Effect of Fraxiparine and heparin on experimental tumor metastasis in mice. Anticancer Res. 2005;25:2869–2872.
   PubMed Web of Science ®Google Scholar
• Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG: Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci. 2004;24:4181– 4186.
   PubMed Web of Science ®Google Scholar
• Kim SK, Lee DY, Kim CY, Moon HT, Byun Y: Prevention effect of orally active heparin derivative on deep vein thrombosis. Thromb Haemost 2006;96:149–153.
   PubMed Web of Science ®Google Scholar
• King MB, Pedtke AC, Levrey-Hadden HL, Hertz MI: Obliterative airway disease progresses in heterotopic airway allografts without persistent alloimmune stimulus. Transplantation. 2002;74:557–562.
   PubMed Web of Science ®Google Scholar
• Antus B, Fillinger J, Sebe A, Jeney C, Horvath I: Late treatment with angiotensin-converting enzyme inhibitors plus endothelin receptor antagonists ameliorates rat tracheal allograft rejection. Transpl Int. 2008;21:801–807.
   PubMed Web of Science ®Google Scholar
• Teranishi K, Poston RS, Reitz BA, Robbins RC: Oral delivery of low molecular weight heparin in rat cardiac allografts. Transplant Proc. 1998;30:996–997.
   PubMed Web of Science ®Google Scholar
• Aziz S, Tada Y, Gordon D, McDonald TO, Fareed J, Verrier ED: A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. J Heart Lung Transplant. 1993;12:634–643.
   PubMed Web of Science ®Google Scholar
• Boehler A, Bai XH, Liu M, Cassivi S, Chamberlain D, Slutsky AS, Keshavjee S: Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med. 1999;159:1910– 1917.
   PubMed Web of Science ®Google Scholar
• Farivar AS, Krishnadasan B, Naidu BV, Woolley SM, Mulligan MS: The role of the beta chemokines in experimental obliterative bronchiolitis. Exp Mol Pathol. 2003;75:210–216.
   PubMed Web of Science ®Google Scholar
• Alho HS, Maasilta PK, Vainikka T, Salminen US: Platelet-derived growth factor, transforming growth factor-beta, and connective tissue growth factor in a porcine bronchial model of obliterative bronchiolitis. Exp Lung Res. 2007;33:303– 320.
   PubMed Web of Science ®Google Scholar
• Aris RM, Walsh S, Chalermskulrat W, Hathwar V, Neuringer IP: Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med. 2002;166:417–422.
   PubMed Web of Science ®Google Scholar
• Kallio EA, Koskinen PK, Aavik E, Buchdunger E, Lemström KB: Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Am J Respir Crit Care Med. 1999;160:1324–1332.
   PubMed Web of Science ®Google Scholar
• Antus B, Barta I, Czebe K, Horvath I, Csiszer E: Analysis of cytokine pattern in exhaled breath condensate of lung transplant recipients with bronchiolitis obliterans syndrome. Inflamm Res. 2010;59:83–86.
   PubMed Web of Science ®Google Scholar
• Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Xue YY, Berlin A, Ross DJ, Kunkel SL, Charo IF, Strieter RM: Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001;108:547–556.
   PubMed Web of Science ®Google Scholar
• Reynaud-Gaubert M, Marin V, Thirion X, Farnarier C, Thomas P, Badier M, Bongrand P, Giudicelli R, Fuentes P: Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant. 2002;21:721–730.
   PubMed Web of Science ®Google Scholar
• Farivar AS, Mackinnon-Patterson B, McCourtie AS, Namkung J, Ward PA, Mulligan MS: Obliterative airway disease in rat tracheal allografts requires tumor necrosis factor alpha. Exp Mol Pathol. 2005;78:190–197.
   PubMed Web of Science ®Google Scholar
• Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL: Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost. 2006;12:267–276.
   PubMed Web of Science ®Google Scholar